Cel-Sci Corporation (CVM) financial statements (2020 and earlier)

Company profile

Business Address 8229 BOONE BLVD .
VIENNA, VA 22182
State of Incorp. CO
Fiscal Year End September 30
SIC 2836 - Biological Products, Except Diagnostic Substances (benchmarking)
More info Complete financial analysis Financial benchmarking

Balance sheet (Statement of financial position) ($ in millions)

9/30/2019
9/30/2018
9/30/2017
9/30/2016
9/30/2015
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments810236
Cash and cash equivalents810236
Receivables00000
Inventory, net of allowances, customer advances and progress billings11111
Inventory11111
Prepaid expense10111
Deferred rent asset    0
Deposits current assets  000
Total current assets:1011459
Noncurrent Assets
Property, plant and equipment161617170
Intangible assets, net (including goodwill)00000
Intangible assets, net (excluding goodwill)00000
Other undisclosed noncurrent assets22226
Total noncurrent assets:181819197
TOTAL ASSETS:2830232515
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities26935
Accounts payable26835
Accrued liabilities00100
Debt  1 0
Derivative instruments and hedges, liabilities120  
Due to related parties11111
Other liabilities0000 
Other undisclosed current liabilities    0
Total current liabilities:391147
Noncurrent Liabilities
Liabilities, other than long-term debt672814
Deferred revenue and credits  0
Other liabilities0000 
Derivative instruments and hedges, liabilities672814
Other undisclosed noncurrent liabilities141413130
Total noncurrent liabilities:1920152214
Total liabilities:2230262621
Stockholders' equity
Stockholders' equity attributable to parent50(3)(1)(5)
Common stock00001
Additional paid in capital359331296285268
Accumulated deficit(354)(332)(300)(285)(274)
Total stockholders' equity:50(3)(1)(5)
TOTAL LIABILITIES AND EQUITY:2830232515

Income statement (P&L) ($ in millions)

9/30/2019
9/30/2018
9/30/2017
9/30/2016
9/30/2015
Gross profit:00001
Operating expenses(21)(17)(21)(24)(35)
Other undisclosed operating income00   
Operating loss:(20)(17)(21)(24)(34)
Nonoperating income (expense)1  (2)(0)
Investment income, nonoperating1    
Interest and debt expense (0)  (1)
Loss from continuing operations before income taxes:(20)(17)(21)(26)(35)
Other undisclosed income from continuing operations   2 
Net loss:(20)(17)(21)(24)(35)
Other undisclosed net income (loss) attributable to parent(2)(15)7120
Net loss attributable to parent:(22)(32)(14)(12)(35)
Other undisclosed net loss available to common stockholders, basic (0)(0)  
Net loss available to common stockholders, basic:(22)(32)(14)(12)(35)
Other undisclosed net loss available to common stockholders, diluted  (1)  
Net loss available to common stockholders, diluted:(22)(32)(15)(12)(35)

Comprehensive Income ($ in millions)

9/30/2019
9/30/2018
9/30/2017
9/30/2016
9/30/2015
Net loss:(20)(17)(21)(24)(35)
Comprehensive loss, net of tax, attributable to parent:(20)(17)(21)(24)(35)

Statements sources

The financial statements are based on the company's filings with the The U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: